Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease

B. K. Binukumar, Varsha Shukla, Niranjana D. Amin, Philip Grant, M. Bhaskar, Susan Skuntz, Joseph Steiner, Harish C. Pant

Research output: Contribution to journalArticle

Abstract

Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by the loss of dopamine neurons in the substantia nigra, decreased striatal dopamine levels, and consequent extrapyramidal motor dysfunction. Recent evidence indicates that cyclin-dependent kinase 5 (Cdk5) is inappropriately activated in several neurodegenerative conditions, including PD. To date, strategies to specifcally inhibit Cdk5 hyperactivity have not been successful without affecting normal Cdk5 activity. Previously we reported that TFP5 peptide has neuroprotective effects in animal models of Alzheimer's disease. Here we show that TFP5/TP5 selective inhibition of Cdk5/p25 hyperactivation in vivo and in vitro rescues nigrostriatal dopaminergic neurodegeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP/MPP+) in a mouse model of PD. TP5 peptide treatment also blocked dopamine depletion in the striatum and improved gait dysfunction after MPTP administration. The neuroprotective effect of TFP5/TP5 peptide is also associated with marked reduction in neuroinfammation and apoptosis. Here we show selective inhibition of Cdk5/p25 hyperactivation by TFP5/TP5 peptide, which identifes the kinase as a potential therapeutic target to reduce neurodegeneration in Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)4478-4491
Number of pages14
JournalMolecular Biology of the Cell
Volume26
Issue number24
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Fingerprint

Cyclin-Dependent Kinase 5
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Parkinson Disease
Peptides
Neuroprotective Agents
Dopamine
Corpus Striatum
Dopaminergic Neurons
Substantia Nigra
Gait
Neurodegenerative Diseases
Alzheimer Disease
Phosphotransferases
Animal Models
Neuroprotection
Apoptosis

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Binukumar, B. K., Shukla, V., Amin, N. D., Grant, P., Bhaskar, M., Skuntz, S., ... Pant, H. C. (2015). Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease. Molecular Biology of the Cell, 26(24), 4478-4491. https://doi.org/10.1091/mbc.E15-06-0415

Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease. / Binukumar, B. K.; Shukla, Varsha; Amin, Niranjana D.; Grant, Philip; Bhaskar, M.; Skuntz, Susan; Steiner, Joseph; Pant, Harish C.

In: Molecular Biology of the Cell, Vol. 26, No. 24, 01.12.2015, p. 4478-4491.

Research output: Contribution to journalArticle

Binukumar, BK, Shukla, V, Amin, ND, Grant, P, Bhaskar, M, Skuntz, S, Steiner, J & Pant, HC 2015, 'Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease', Molecular Biology of the Cell, vol. 26, no. 24, pp. 4478-4491. https://doi.org/10.1091/mbc.E15-06-0415
Binukumar, B. K. ; Shukla, Varsha ; Amin, Niranjana D. ; Grant, Philip ; Bhaskar, M. ; Skuntz, Susan ; Steiner, Joseph ; Pant, Harish C. / Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease. In: Molecular Biology of the Cell. 2015 ; Vol. 26, No. 24. pp. 4478-4491.
@article{bdd69225b3044bce89d863ea54b77737,
title = "Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease",
abstract = "Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by the loss of dopamine neurons in the substantia nigra, decreased striatal dopamine levels, and consequent extrapyramidal motor dysfunction. Recent evidence indicates that cyclin-dependent kinase 5 (Cdk5) is inappropriately activated in several neurodegenerative conditions, including PD. To date, strategies to specifcally inhibit Cdk5 hyperactivity have not been successful without affecting normal Cdk5 activity. Previously we reported that TFP5 peptide has neuroprotective effects in animal models of Alzheimer's disease. Here we show that TFP5/TP5 selective inhibition of Cdk5/p25 hyperactivation in vivo and in vitro rescues nigrostriatal dopaminergic neurodegeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP/MPP+) in a mouse model of PD. TP5 peptide treatment also blocked dopamine depletion in the striatum and improved gait dysfunction after MPTP administration. The neuroprotective effect of TFP5/TP5 peptide is also associated with marked reduction in neuroinfammation and apoptosis. Here we show selective inhibition of Cdk5/p25 hyperactivation by TFP5/TP5 peptide, which identifes the kinase as a potential therapeutic target to reduce neurodegeneration in Parkinson's disease.",
author = "Binukumar, {B. K.} and Varsha Shukla and Amin, {Niranjana D.} and Philip Grant and M. Bhaskar and Susan Skuntz and Joseph Steiner and Pant, {Harish C.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1091/mbc.E15-06-0415",
language = "English (US)",
volume = "26",
pages = "4478--4491",
journal = "Molecular Biology of the Cell",
issn = "1059-1524",
publisher = "American Society for Cell Biology",
number = "24",

}

TY - JOUR

T1 - Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease

AU - Binukumar, B. K.

AU - Shukla, Varsha

AU - Amin, Niranjana D.

AU - Grant, Philip

AU - Bhaskar, M.

AU - Skuntz, Susan

AU - Steiner, Joseph

AU - Pant, Harish C.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by the loss of dopamine neurons in the substantia nigra, decreased striatal dopamine levels, and consequent extrapyramidal motor dysfunction. Recent evidence indicates that cyclin-dependent kinase 5 (Cdk5) is inappropriately activated in several neurodegenerative conditions, including PD. To date, strategies to specifcally inhibit Cdk5 hyperactivity have not been successful without affecting normal Cdk5 activity. Previously we reported that TFP5 peptide has neuroprotective effects in animal models of Alzheimer's disease. Here we show that TFP5/TP5 selective inhibition of Cdk5/p25 hyperactivation in vivo and in vitro rescues nigrostriatal dopaminergic neurodegeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP/MPP+) in a mouse model of PD. TP5 peptide treatment also blocked dopamine depletion in the striatum and improved gait dysfunction after MPTP administration. The neuroprotective effect of TFP5/TP5 peptide is also associated with marked reduction in neuroinfammation and apoptosis. Here we show selective inhibition of Cdk5/p25 hyperactivation by TFP5/TP5 peptide, which identifes the kinase as a potential therapeutic target to reduce neurodegeneration in Parkinson's disease.

AB - Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by the loss of dopamine neurons in the substantia nigra, decreased striatal dopamine levels, and consequent extrapyramidal motor dysfunction. Recent evidence indicates that cyclin-dependent kinase 5 (Cdk5) is inappropriately activated in several neurodegenerative conditions, including PD. To date, strategies to specifcally inhibit Cdk5 hyperactivity have not been successful without affecting normal Cdk5 activity. Previously we reported that TFP5 peptide has neuroprotective effects in animal models of Alzheimer's disease. Here we show that TFP5/TP5 selective inhibition of Cdk5/p25 hyperactivation in vivo and in vitro rescues nigrostriatal dopaminergic neurodegeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP/MPP+) in a mouse model of PD. TP5 peptide treatment also blocked dopamine depletion in the striatum and improved gait dysfunction after MPTP administration. The neuroprotective effect of TFP5/TP5 peptide is also associated with marked reduction in neuroinfammation and apoptosis. Here we show selective inhibition of Cdk5/p25 hyperactivation by TFP5/TP5 peptide, which identifes the kinase as a potential therapeutic target to reduce neurodegeneration in Parkinson's disease.

UR - http://www.scopus.com/inward/record.url?scp=84949058159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949058159&partnerID=8YFLogxK

U2 - 10.1091/mbc.E15-06-0415

DO - 10.1091/mbc.E15-06-0415

M3 - Article

VL - 26

SP - 4478

EP - 4491

JO - Molecular Biology of the Cell

JF - Molecular Biology of the Cell

SN - 1059-1524

IS - 24

ER -